The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income | 8,510 | 480 | 5,613 | 4,566 |
| Depreciation expense | 370 | 381 | 354 | 323 |
| Amortization expense | 2,390 | 2,386 | 2,339 | 1,780 |
| Stock-based compensation expense | 894 | 835 | 766 | 637 |
| Deferred income taxes | 160 | -1,844 | -962 | -1,552 |
| Net (gain) loss from equity securities | 451 | -274 | -167 | -657 |
| Acquired in-process research and development expenses | 1,024 | 4,663 | 1,155 | 944 |
| In-process research and development impairments | 590 | 4,180 | 50 | 2,700 |
| Other, net | -480 | -353 | -826 | -780 |
| Accounts receivable, net | 367 | -139 | -157 | 406 |
| Inventories | 1,036 | 426 | 842 | 310 |
| Prepaid expenses and other | 311 | 259 | -39 | -70 |
| Accounts payable | -132 | 290 | -347 | 226 |
| Income taxes payable | - | - | - | -568 |
| Income tax assets and liabilities, net | -2,108 | -732 | -1,768 | - |
| Accrued and other liabilities | 6 | 108 | 458 | -775 |
| Net cash provided by operating activities | 10,019 | 10,828 | 8,006 | 9,072 |
| Purchases of marketable debt securities | 3,939 | 244 | 1,930 | 1,770 |
| Proceeds from sales of marketable debt securities | 854 | 2,265 | 510 | 412 |
| Proceeds from maturities of marketable debt securities | 55 | 327 | 1,334 | 1,590 |
| Acquisitions, including in-process research and development, net of cash acquired | 1,070 | 4,840 | 1,152 | 1,797 |
| Purchases of equity securities | 133 | 492 | 442 | 172 |
| Purchases of property, plant and equipment | 563 | 523 | 585 | 728 |
| Other investing activities, net | -2 | -58 | 1 | 1 |
| Net cash used in investing activities | -4,793 | -3,449 | -2,265 | -2,466 |
| Proceeds from debt financing, net of issuance costs | 0 | 3,464 | 1,980 | 0 |
| Proceeds from issuances of common stock | 408 | 422 | 232 | 309 |
| Repurchases of common stock under repurchase programs | 1,922 | 1,150 | 1,000 | 1,396 |
| Repayments of debt and other obligations | 1,788 | 1,970 | 2,250 | 1,500 |
| Payments of dividends | 4,003 | 3,918 | 3,809 | 3,709 |
| Other financing activities, net | -440 | -281 | -279 | -173 |
| Net cash used in financing activities | -7,745 | -3,433 | -5,125 | -6,469 |
| Effect of exchange rate changes on cash and cash equivalents | 92 | -40 | 57 | -63 |
| Net change in cash and cash equivalents | -2,428 | 3,906 | 673 | 74 |
| Cash and cash equivalents at beginning of period | 9,991 | 6,085 | 5,412 | 5,338 |
| Cash and cash equivalents at end of period | 7,564 | 9,991 | 6,085 | 5,412 |
GILEAD SCIENCES, INC. (GILD)
GILEAD SCIENCES, INC. (GILD)